The world's best-selling runner-up varieties local three male competition for food!

is the core drug for the treatment of multiple myeloma, which is recommended as a class of therapeutic drugs by the relevant guidelines of multiple myeloma at home and abroad., with the domestic generic drug consistency evaluation work and with the volume of procurement further advanced, the winning enterprises have gradually obtained benefits. Local enterprises to the nadamine generic drugs listed in succession, the drug will gradually achieve localization. In the future, China's generic drug market will be more intense competition, high-quality generic drugs will become the main market force.leader in oncologyranked third in the world's best-selling drug TOP10 in 2018, up 18.3 percent from the same period last year. In 2018, the global anti-tumor drug TOP10, the new base of the amine ranked No. 1. Professionals predict that the growth momentum of the amine will continue to grow rapidly in the coming years, with global sales forecast of $10.9 billion in 2019, and it remains a leader in the field of oncology.2005, the new base of the amine market in the year of global sales of only 0.03 billion U.S. dollars, in 2007 exceeded 500 million U.S. dollars, in 2008 exceeded 1 billion U.S. dollars, in 2010 exceeded 2 billion U.S. dollars, in 2012 exceeded 3 billion Dollars, which exceeded $4 billion in 2013, $5 billion in 2014, nearly $6 billion in 2015, nearly $7 billion in 2016, $8 billion in 2017 and nearly $10 billion in sales in 2018. One big step a year, the growth is very fast. According to The New Base's first-quarter 2019 results, sales of amines were $2.577 billion, up 15% year-on-year.The global growth rate is a bit rapidthe original drug developed by Xinji, approved by the FDA in December 2005, the commodity is called "Revlimid", in June 2007 approved by the European Medicines Agency (EMA) listed, on June 25, 2010 by the Japanese PMDA approved for listing. In 2018, the world's most popular anti-tumor drug TOP10 topped the list with sales of $9.685 billion. In recent years, the global sales of nadamine have been maintaining double-digit growth, the market potential is huge.January 2013, xinji's amine was approved to enter China, the commodity named "Rui Fumei", the dosage form is capsule, the specifications are 5mg, 10mg, 15mg, 25mg. According to domestic sample hospital statistics, in 2018, the terminal sales of the hospital were 142 million yuan, an increase of 547.3 percent over the previous year, a rapid growth rate.The Chinese market later "overdride"at present, in addition to the original research manufacturer's new base products, there are shuangqi pharmaceutical industry, Zhengda Tianqing and Qilu pharmaceutical products to participate in the competition. Among them, Beijing Shuangdao Pharmaceuticals in accordance with the new drug 3.1 class, Zhengda Tianqing Pharmaceutical products according to generic drugs 6 categories of declaration and approved production, still need to pass the consistent evaluation, the two enterprises have submitted a consistent evaluation of supplementary applications. On April 25th, Qilu Pharmaceutical's Lanadoamine capsule was approved for listing by the State Drug Administration, and the product was declared on the market in class 4 generic drugs, and was approved for production as if it had passed a consistent evaluation. This is the second time qilu Pharmaceuticals has been approved for another pound of the blood system's anti-tumor drug following the introduction of injection boron tazome in 2017. Qilu Pharmaceuticals has become a domestic company with two majority of myeloma drugs.National enterprises sanxiong competition to nada amine compound patent expired in July 2017, in addition to the original research enterprises and three local enterprises Shuangji, Zhengda Tianqing and Qilu Pharmaceutical products on the market, there are many domestic enterprises in the accelerated layout.November 2017, Shuangda Pharmaceuticals' Lynadamine capsules were listed for the first time in China, and in January 2019, a second imitation of the amine capsules was launched. Qilu Pharmaceuticals is the third company in China to be approved for the listing of nadamine, but for the first review, in the next tender procurement will occupy a dominant position.according to domestic sample hospital drug use statistics, the amount of amine use since 2013 was 1.75 million yuan, in 2014 it was 10.78 million yuan, in 2015 it was 13.56 million yuan, in 2016 it was 19.21 million yuan, in 2017 it was 22.02 million yuan, and in 2018 it was 143 million yuan. Sales of the drug have not grown very fast in the five years since it went on the market, and will grow rapidly in 2018. Analysis of its reasons, the previous growth rate is not fast mainly due to the high price of imported drugs, in the domestic market some water and soil do not accept. But the market has changed a lot in 2018 after the product entered the health insurance catalog.July 19, 2017, 36 negotiated drugs, including amines, were included in category B of the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2017 edition). Since August 2018, some countries have adjusted the price of anti-cancer drugs negotiated in some early stages, and the price paid for health insurance for 10mg and 25mg of amines is 811 yuan/grain and 1030 yuan/granules, respectively. After the product entered the health insurance catalog, the original research product price reduction, coupled with the impact of generic drugs on the original research products, the market began to have a good performance in 2018. (Medical Economics)